Report Publication Announcement • Jan 3, 2017
Report Publication Announcement
Open in ViewerOpens in native device viewer
Regulated information
Brussels, Belgium, January 3, 2017 – ASIT biotech (ASIT - BE0974289218), a Belgian clinical-stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough immunotherapy products for the treatment of allergies, today announces its preliminary financial calendar for 2017.
| Event | Date * |
|---|---|
| 2016 Full-Year Results | Friday, April 21, 2017 |
| Shareholders' General Meeting | Thursday, June 8, 2017 |
| 2017 Half-Year Results | Friday, September 15, 2017 |
Financial year ended December 31
* Subject to modification. Press releases are distributed before the financial markets open.
***
ASIT biotech is a Belgian clinical stage biopharmaceutical company focused on the development and future commercialisation of a range of breakthrough immunotherapy products for the treatment of allergies. Thanks to its innovative ASIT+TM technology platform, ASIT biotech is currently the only developer of AIT product candidates consisting of a unique mixture of highly purified natural allergen fragments in an optimal size selection. This innovation results in a short treatment, expected to improve patient compliance and real-life effectiveness. ASIT biotech's product pipeline entails two novel ASIT+™ product candidates targeting respiratory allergy with the highest prevalence (i.e. grass pollen: gp-ASIT+TM and house dust mite: hdm-ASIT+TM), that could significantly expand the current immunotherapy market. The Company believes that its innovative ASIT+™ platform is flexible and would be applicable across a range of allergies.
ASIT biotech has a headcount of 22 staff members, at its headquarters in Brussels and a laboratory in Liège, Belgium.
Further information can be found at: www.asitbiotech.com.
Thierry Legon, CEO ASIT biotech Tel. +32 2 264 03 90 [email protected]
Media and Investor Relations - France NewCap Dusan Oresansky / Pierre Laurent Tel.: +33 1 44 71 94 92 [email protected]
Laure-Eve Monfort Tel.: +32 2 290 90 93 [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.